| P50 | author | Peter Tugwell | Q28036951 |
| | Doug Coyle | Q42156336 |
| P2093 | author name string | Ann Cranney | |
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| | Multi-attribute health status classification systems. Health Utilities Index | Q33569094 |
| | Hormone therapy to prevent disease and prolong life in postmenopausal women | Q34262585 |
| | Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women | Q34290508 |
| | Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women | Q34803319 |
| | Measuring the impact of menopausal symptoms on quality of life | Q35189663 |
| | Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial | Q39443195 |
| | A cost-effectiveness analysis of hormone replacement therapy in the menopause | Q39503065 |
| | Cost-effectiveness of hormone replacement therapy in the menopause. | Q39558708 |
| | Combined continuous hormone replacement therapy: a critical review. | Q40448413 |
| | Hormone replacement therapy: aspects of bleeding problems and compliance. | Q41010079 |
| | Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments | Q41178902 |
| | Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation | Q43682728 |
| | HRT: an analysis of benefits, risks and costs | Q44551064 |
| | Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis | Q45040818 |
| | Economic implications of hip fracture: health service use, institutional care and cost in Canada. | Q50676483 |
| | Cost-effectiveness of fracture prevention in established osteoporosis. | Q50921107 |
| | The psychometric properties of patient preferences in osteoporosis. | Q53497402 |
| | The Pharmacoeconomics of Hormone Replacement Therapy | Q56888467 |
| | Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium | Q56888537 |
| | Cost-effectiveness of hormone replacement | Q68344798 |
| | The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms | Q73322360 |
| | Adherence to postmenopausal hormone therapy during the year after the initial prescription: A population-based study | Q73492085 |
| | Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators | Q74228722 |
| | Compliance considerations with hormone replacement therapy | Q74832818 |
| | Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group | Q78016942 |
| P433 | issue | 9 | |
| P304 | page(s) | 661-669 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms | |
| P478 | volume | 21 | |